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tional length, litter size, and perinatal mortality in the off-
spring were assessed.  Results: After subcutaneous injection 
with a high dose of LPS, we observed a significant decrease 
in gestational length and an increase in neonatal mortality. 
When the low dose was administered, a tendency towards a 
reduced litter size was observed, most likely reflecting in-
creased intrauterine mortality in response to prenatal mater-
nal LPS exposure.  Conclusions: We showed that subcutane-
ous administration of 2 mg/kg LPS to pregnant mice in the 
last phase of gestation should be avoided because of high 
offspring mortality rates, whereas subcutaneous injection of 
0.5 mg/kg LPS seems to result in reabsorption of the fetuses. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Infection during pregnancy has been reported to in-
crease the susceptibility of the offspring to developing 
psychopathology later in life  [1, 2] . For instance, increased 
risks of schizophrenia, bipolar disorder, and autism have 
been reported in the offspring of women infected with 
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 Abstract 
 Background: Infection during pregnancy can predispose 
offspring to develop various psychiatric disorders such as 
depression in later life. In order to investigate the potential 
mechanisms underlying these associations, animal models 
of maternal infection have been employed. As such, lipo-
polysaccharide (LPS) has been commonly used to mimic a 
bacterial infection in pregnant mice.  Objective: The original 
aim of our study was to investigate the effects of different 
doses of subcutaneous LPS administration on affective be-
havior in adult mouse offspring. In the present paper, how-
ever, we report that subcutaneous LPS administration has a 
profound impact on gestational length, litter size, and peri-
natal mortality in the offspring, even at a relatively low dose. 
 Methods: Pregnant mice were randomly divided into 3 
groups, receiving either a high (2 mg/kg) or a low (0.5 mg/
kg) dose of LPS or phosphate-buffered saline by means of 
subcutaneous injection. Subsequently, the effects on gesta-
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viruses or bacteria during pregnancy  [3–5] . In order to 
investigate the potential mechanisms underlying these 
associations, animal models of maternal infection have 
been employed. As such, lipopolysaccharide (LPS) has 
been commonly used to mimic a bacterial infection in 
pregnant mice. Through Toll-like receptor 4 (TLR4), LPS 
increases the production of proinflammatory cytokines, 
which are known to interfere with the development of the 
central nervous system  [6] . In the fetal brain, cytokines 
are known to regulate the function and development of 
neurons, being involved in neuroprotective and neurode-
generative processes  [7] . Different effects of LPS in ro-
dents have been reported, such as modulation of the hy-
pothalamus-pituitary-adrenal axis, resulting in increased 
corticosterone levels  [8] . After LPS exposure during ges-
tation, several behavioral changes have been observed in 
the offspring in adulthood (e.g. impairments in spatial 
learning and memory)  [9–11] .
 Intraperitoneal (i.p.) injection of LPS in pregnant 
mothers is known to result in fetal death depending on 
the dose administered  [12] . In addition to the dose in-
jected, the time point of LPS injection plays an important 
role in relation to changes in the protein levels of cyto-
kines in the brains of fetuses  [13] . It is noteworthy that the 
great majority of prenatal LPS studies have used i.p. injec-
tions in pregnant mice  [12–16] . Considering the fact that 
i.p. injections have a failure rate in the order of 10–20% 
 [17] , subcutaneous (s.c.) injections may be favored – par-
ticularly when dealing with pregnant animals, where mis-
placement of the injection can cause severe damage to 
both the mother and the fetus. However, little is known 
about the potentially adverse effects of s.c. LPS injections 
in pregnant animals. Whereas originally the aim of our 
study was to investigate the effects of different doses of 
s.c. LPS on affective behavior in adult offspring, in the 
present paper we report that s.c. LPS administration, even 
at a relatively low dose, has a profound impact on gesta-
tional length, litter size, and perinatal mortality in the off-
spring.
 Material and Methods 
 Animals 
 C57BL/6JRccHsd mice were obtained from Harlan Laborato-
ries (Eystrup, Germany). The mice were housed 4 per cage in sin-
gle-sex groups in individually ventilated cages sized 480 × 375 × 
210 mm (depth × width × height) under specified pathogen-free 
conditions and maintained on a 12-/12-hour light-dark cycle 
(lights on at 12.00 a.m.) and in a temperature-controlled environ-
ment (relative humidity: 55 ± 5%; temperature: 22 ± 2   °   C, and 
room air exchange rate: 15). The mice were s.c. injected with a 
transponder for identification purposes. Breeding food (Ssniff, 
Germany) and water were allowed ad libitum. Cages were changed 
every week. The experiments were conducted with permission 
from the government and the veterinarian administration of Up-
per Bavaria (AZ: 55.2-1-54-2531-61-10). After arriving at the local 
animal facilities, the mice were allowed to habituate to their new 
environment for 3 weeks. During this period, the mice were 
chipped to facilitate their identification. For mating, females were 
housed together with a male mouse for 3 days (1 male and 1 female 
per cage). Afterwards, females were housed individually. Three 
weeks after delivery, the offspring were weaned and separated by 
sex (4 mice/cage). The offspring were chipped when they were 
6 weeks old.
 Mating and Induction of Prenatal Infection 
 Approximately 8 weeks after birth, male and female mice 
were coupled again for 3 days. On gestational day 17, pregnancy 
was confirmed by visual inspection of the dam in combination 
with weight gain analysis (increase between the day of mating 
and the day of injection). Pregnant mice were randomly divided 
into 3 groups [high dose of LPS (n = 21), low dose of LPS (n = 
16), and phosphate-buffered saline (n = 20)]. Dams were s.c. in-
jected with 0.5 or 2 mg/kg LPS (from  Salmonella enterica sero-
type enteritidis; Sigma Aldrich, Germany) or an equivalent vol-
ume of phosphate-buffered saline. Following injection, the mice 
were observed daily until delivery. Postnatal mortality was cal-
culated by comparing the number of born pups found dead and 
the total number of pups counted during the observation period. 
Of note, when assessing postnatal mortality, 4 animals were ex-
cluded in the group treated with a low dose of LPS as these 4 
animals were confirmed to be pregnant on gestational day 17 but 
never delivered.
 Statistical Analysis 
 To define statistically significant differences in gestational 
length, litter size, and mortality, data were first subjected to an 
analysis of variance (ANOVA) using IBM SPSS Statistics 20 (SPSS 
Inc., USA). Significant overall effects were subsequently examined 
in more detail using post hoc Bonferroni tests. p < 0.05 was con-
sidered statistically significant in all cases.
 Results 
 Overall, significant effects of LPS administration were 
found for gestational length (F 2, 54  = 26.366; p < 0.001) and 
neonatal mortality (F 2, 50   = 93.997; p  < 0.001), while a 
trend towards a significant effect on litter size (F 2, 54   = 
2.700; p = 0.076) was observed ( fig. 1 ). Already 1 day after 
injection, some dams treated with the high dose of LPS 
started to deliver. This led to a significant decrease in ges-
tational length in mothers treated with the high dose of 
LPS compared to the control group (p < 0.001), while no 
difference in gestational length was observed between 
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dams (p = 1). LPS mothers given the high dose showed a 
reduction in gestational length compared to those inject-
ed with a low dose (p < 0.001). In addition, the litter size 
tended to be reduced in dams injected with a low dose of 
LPS compared to the controls, although this difference 
did not reach statistical significance (p = 0.095). Further, 
no significant differences were observed between the high 
dose of LPS and the controls (p = 1) or between the two 
doses of LPS (p  = 0.211). A remarkable effect was ob-
served in relation to neonatal mortality. After injection of 
the high dose of LPS, almost all pups died within a few 
days after birth (>95%), whereas the mortality in the con-
trol offspring was almost negligible (1.5%; p < 0.001). A 
mortality rate of 16.67% was detected following adminis-
tration of the low dose of LPS, but this effect did not reach 
significance compared to the controls (p = 0.233). When 
comparing both doses of LPS, a significant increase in 
mortality was observed in pups from mothers injected 
with a high dose of LPS (p < 0.001).
 Discussion 
 In the present paper, we report that s.c. LPS adminis-
tration in the mouse has a profound impact on gestation-
al length, litter size, and perinatal mortality in the off-
spring, even at a relatively low dose. More specifically, our 
study showed that s.c. administration of LPS at a dose of 
2 mg/kg in pregnant mice resulted in a significant reduc-
tion in gestational length and a high  neonatal mortality 
rate, whereas s.c. injection of 0.5 mg/kg LPS seemed to be 
associated with an increased  prenatal mortality, reflecting 
reabsorption of the fetuses.
 Route of Administration 
 Whereas other publications have reported similar ef-
fects after prenatal LPS administration, the exact effects 
seem to largely depend on the dose, the route of admin-
istration, and the gestational day of exposure or on the 
combination of these factors  [18, 19] . Most of the studies 
have used i.p. administration of LPS [e.g.  14, 16 ], while 
little is known about other ways of administration such as 
intrauterine or intravenous injection  [20, 21] . Important-
ly, between 10 and 20% of regular i.p. injections were 
placed not in the peritoneal cavity but rather in the intes-
tine or the stomach and this frequency could not be min-
imized after modification of the procedure  [17, 22, 23] . In 
fact, in the case of injection of pregnant dams, such ad-
verse effects may be expected to be even worse, including 
direct harm to the fetus. In addition, other disadvantages 
such as splenic trauma, serosal hemorrhage, and contam-
ination have been reported  [24] . Hence, s.c. injection may 
represent a more suitable route of administration when 
































































 Fig. 1. Overall, significant LPS effects were found on gestational 
length (F 2, 54  = 26.366; p < 0.001) and mortality (F 2, 50  = 93.997; p < 
0.001), while a trend towards a significant effect on litter size 
(F 2, 54  = 2.700; p = 0.076) was observed.  a More specifically, a re-
duced gestational length was observed after s.c. administration of 
a high dose of LPS compared to controls (p < 0.001). A similar ef-
fect was found when analyzing both doses of LPS (p < 0.001).  b The 
litter size tended to be reduced after treatment with a low dose of 
LPS (p = 0.095) compared to controls.  c After s.c. injection with 
the high dose of LPS, neonatal mortality was increased compared 
to values for both the low dose of LPS (p < 0.001) and the controls 
(p < 0.001). Bars represent means ± SE.  #  p < 0.1,  ##  p < 0.001 
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 Dose-Dependent Effect on Prenatal and Neonatal 
Mortality 
 As mentioned above, the dose of LPS and the timing 
of the injection are considered critical factors that may 
impact fetal death. However, to date, no report has indi-
cated which dose of s.c. LPS is sufficient to trigger a re-
sponse in the mother and fetus without causing death. A 
limited number of articles have been published studying 
the effects of zinc supplementation and teratogenicity 
after prenatal exposure to LPS  [25–27] . However, no ev-
idence has been reported on effects on intrauterine or 
neonatal mortality, litter size, or gestational length. In 
the present study, the litter size tended to be reduced 
when using a low dose of LPS. In fact, 4 females within 
this group were confirmed to be pregnant at the time of 
LPS injection (gestational day 17) but never delivered, 
pointing to reabsorption of the fetuses. Interestingly, it 
has been reported that prenatal maternal i.p. administra-
tion of high doses of LPS causes fetal resorption, where-
as exposure to low doses results in normal delivery  [13] . 
Counterintuitively, we only observed a reduction in lit-
ter size after prenatal administration of a low dose of LPS 
but not after using a high dose. This lack of an effect 
when using the high dose could be explained by the fact 
that the high dose of LPS induced an abrupt  premature 
delivery, concomitant with a massive increase in  neona-
tal  – instead of  prenatal  – mortality, allowing no oppor-
tunity for intrauterine absorption.  Although it was ex-
pected that some pups would die  after exposure to LPS, 
the high rate of neonatal mortality (>95%) observed af-
ter administration of the high dose of LPS compared to 
the low dose (16.67%) was  remarkable.
 Concluding Remarks 
 Evidently, it would be useful to find out more about 
the exact effects of prenatal LPS administration in pups 
when using different doses, routes, and time points of 
administration in order to choose a suitable exposure 
for future experiments. Although most problems are to 
be expected when using i.p. injections, this route of ad-
ministration is still mostly employed in mouse models. 
Therefore, we investigated the effects of different doses 
of LPS using s.c. injections. In our study, using s.c. LPS 
injections we could avoid the problem of misplacing the 
agent or directly harming the fetus when injecting the 
pregnant dams. Altogether, we conclude that s.c. LPS 
administration in the mouse had a profound impact on 
gestational length, litter size, and perinatal mortality in 
the offspring, even at a relatively low dose. Future work 
should elucidate to which extent lower doses of LPS in-
duce short- and/or long-term behavioral changes in the 
offspring and which exact molecular mechanisms are 
involved.
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Erratum
In the article by Nascimento AF, Alves GJ, Massoco CO, Teodorov E, Felicio LF and Ber-
nardi MM, entitled ‘Lipopolysaccharide-Induced Sickness Behavior in Lactating Rats De-
creases Ultrasonic Vocalizations and Exacerbates Immune System Activity in Male Off-
spring’ [Neuroimmunomodulation 2015;22, DOI: 10.1159/000363350], an error occurred 
in table 1 and in the text.
Please find below the corrected table row and text passage.
Section Discussion, page 6, second column, second paragraph, line 7 from the bottom: 
Therefore, the decrease in the latency to retrieve the third pup observed in lactating LPS-
treated rats in the present study may be attributable to a slight improvement in maternal 
care.
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